Pharmaceutical company Pfizer has warned the United States administration that it is impossible to produce enough COVID-19 vaccine for delivery. All because other countries have bought up most of the stock, the National News Service reports.
In addition, insufficient quantities could have a negative impact on the vaccine schedule in the United States.
Another problem with the supply of Pfizer vaccine is due to difficulties with logistics. For example, the storage temperature of a drug must be -70 degrees Celsius.
Recall that in summer the U.S. administration signed a contract with Pfizer and the German company BioNTech to purchase 600 million doses of vaccine worth $195 billion.
Earlier it became known that the first western country where vaccination against coronavirus started was Great Britain.